Takeda Pharmaceutical Net Income 2007-2018 | TAK

Takeda Pharmaceutical annual/quarterly net income history and growth rate from 2007 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Takeda Pharmaceutical net income for the quarter ending December 31, 2018 was $0.336B, a 66.74% increase year-over-year.
  • Takeda Pharmaceutical net income for the twelve months ending December 31, 2018 was $3.285B, a 357.56% decline year-over-year.
  • Takeda Pharmaceutical annual net income for 2018 was $1.682B, a 57.35% increase from 2017.
  • Takeda Pharmaceutical annual net income for 2017 was $1.069B, a 60.65% increase from 2016.
  • Takeda Pharmaceutical annual net income for 2016 was $0.665B, a 150.16% decline from 2015.
Takeda Pharmaceutical Annual Net Income
(Millions of US $)
2018 $1,682
2017 $1,069
2016 $665
2015 $-1,327
2014 $1,067
2013 $1,588
2012 $1,577
2011 $2,986
2010 $3,202
2009 $2,392
2008 $3,555
2007 $2,846
2006 $2,677
Takeda Pharmaceutical Quarterly Net Income
(Millions of US $)
Q3 2018 $336
Q1 2018 $720
Q1 2017 $1,303
Q1 2016 $926
Q1 2015 $202
Q4 2015 $-1,892
Q3 2014 $156
Q2 2014 $260
Q1 2014 $326
Q4 2014 $-43
Q3 2013 $457
Q2 2013 $360
Q1 2013 $296
Q4 2013 $462
Q3 2012 $236
Q2 2012 $409
Q1 2012 $1,119
Q4 2012 $-460
Q3 2011 $322
Q2 2011 $775
Q4 2011 $394
Q4 2010 $426
Q2 2009 $-1
Q4 2009 $705
Q4 2008 $-922
Q4 2007 $583
Q4 2006 $275
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $28.529B $15.988B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $47.980B 31.89
Grifols (GRFS) Spain $12.699B 15.52
Ionis Pharmaceuticals (IONS) United States $10.053B 31.18
Sage Therapeutics (SAGE) United States $7.794B 0.00
Neurocrine Biosciences (NBIX) United States $7.309B 471.06
Jazz Pharmaceuticals (JAZZ) Ireland $7.187B 10.29
Catalent (CTLT) United States $6.414B 26.85
Nektar Therapeutics (NKTR) United States $5.397B 8.61
Tilray (TLRY) United States $5.016B 0.00
United Therapeutics (UTHR) United States $4.322B 7.35
Taro Pharmaceutical Industries (TARO) Israel $4.140B 13.33
FibroGen (FGEN) United States $4.007B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.832B 0.00
Portola Pharmaceuticals (PTLA) United States $2.302B 0.00
PTC Therapeutics (PTCT) United States $2.111B 0.00
USANA Health Sciences (USNA) United States $1.908B 16.01
Xencor (XNCR) United States $1.800B 0.00
Heron Therapeutics (HRTX) United States $1.798B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.769B 0.00
Aerie Pharmaceuticals (AERI) United States $1.759B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.746B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.625B 20.24
Madrigal Pharmaceuticals (MDGL) United States $1.615B 0.00
Endo (ENDP) Ireland $1.604B 2.47
Pacira Pharmaceuticals (PCRX) United States $1.598B 138.39
Zogenix (ZGNX) United States $1.578B 0.00
Corcept Therapeutics (CORT) United States $1.408B 20.45
Tricida (TCDA) United States $1.336B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.288B 0.00
Esperion Therapeutics (ESPR) United States $1.123B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.052B 0.00
TherapeuticsMD (TXMD) United States $1.023B 0.00
Radius Health (RDUS) United States $0.973B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.899B 0.00
CannTrust Holdings (CTST) Canada $0.776B 0.00
Akebia Therapeutics (AKBA) United States $0.767B 0.00
ChemoCentryx (CCXI) United States $0.715B 0.00
ArQule (ARQL) United States $0.698B 0.00
Dermira (DERM) United States $0.598B 0.00
Odonate Therapeutics (ODT) United States $0.586B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.582B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.576B 0.00
Forty Seven (FTSV) United States $0.563B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.554B 0.00
GlycoMimetics (GLYC) United States $0.538B 0.00
TCR2 THERAPTCS (TCRR) United States $0.502B 0.00
Collegium Pharmaceutical (COLL) United States $0.472B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.459B 23.68
KalVista Pharmaceuticals (KALV) United States $0.455B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.448B 0.00
Translate Bio (TBIO) United States $0.447B 0.00
Siga Technologies (SIGA) United States $0.423B 0.00
OptiNose (OPTN) United States $0.411B 0.00
Flexion Therapeutics (FLXN) United States $0.389B 0.00
Aptorum Group (APM) China $0.388B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.376B 0.00
ImmunoGen (IMGN) United States $0.347B 0.00
Mast Therapeutics (SVRA) United States $0.346B 0.00
CASI Pharmaceuticals (CASI) United States $0.317B 0.00
Karyopharm Therapeutics (KPTI) United States $0.295B 0.00
Lannett Co Inc (LCI) United States $0.284B 2.63
Minerva Neurosciences (NERV) United States $0.282B 0.00
Harpoon Therapy (HARP) United States $0.276B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.268B 9.93
AcelRx Pharmaceuticals (ACRX) United States $0.268B 0.00
Xeris Pharmaceuticals (XERS) United States $0.252B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.247B 0.00
Aclaris Therapeutics (ACRS) United States $0.243B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.238B 0.00
Dova Pharmaceuticals (DOVA) United States $0.236B 0.00
Calithera Biosciences (CALA) United States $0.236B 0.00
Molecular Templates (MTEM) United States $0.226B 0.00
Concert Pharmaceuticals (CNCE) United States $0.223B 0.00
Rafael Holdings (RFL) United States $0.216B 0.00
MEI Pharma (MEIP) United States $0.213B 0.00
Ardelyx (ARDX) United States $0.212B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.211B 0.00
Opexa Therapeutics (ACER) United States $0.207B 0.00
Affimed (AFMD) Germany $0.206B 0.00
Aldeyra Therapeutics (ALDX) United States $0.202B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.194B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.191B 0.00
Galectin Therapeutics (GALT) United States $0.189B 0.00
Nature's Sunshine Products (NATR) United States $0.184B 191.20
Recro Pharma (REPH) United States $0.181B 0.00
Jounce Therapeutics (JNCE) United States $0.180B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.178B 0.00
Neon Therapeutics (NTGN) United States $0.176B 0.00
Majesco Entertainment (PTE) United States $0.175B 0.00
IMV INC (IMV) Canada $0.175B 0.00
ElectroCore (ECOR) United States $0.175B 0.00
Redhill Biopharma (RDHL) Israel $0.173B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.170B 0.00
AgeX Therapeutics (AGE) United States $0.167B 0.00
Aratana Therapeutics (PETX) United States $0.165B 0.00
Ocular Therapeutix (OCUL) United States $0.157B 0.00
Tyme Technologies (TYME) United States $0.157B 0.00
Aquestive Therapeutics (AQST) United States $0.156B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.147B 0.00
MediWound (MDWD) Israel $0.133B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.133B 0.00
China SXT Pharmaceuticals (SXTC) China $0.119B 0.00
Iterum Therapeutics (ITRM) Ireland $0.114B 0.00
ProNAi Therapeutics (SRRA) Canada $0.108B 0.00
Cardiome Pharma (CORV) Canada $0.106B 0.00
Neos Therapeutics (NEOS) United States $0.100B 0.00
Nivalis Therapeutics (ALPN) United States $0.100B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.099B 0.00
Natural Alternatives (NAII) United States $0.096B 9.37
Champions Oncology (CSBR) United States $0.095B 0.00
Zafgen (ZFGN) United States $0.094B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.092B 0.00
DURECT (DRRX) United States $0.092B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.091B 0.00
Adherex Technologies (FENC) United States $0.089B 0.00
Bio Blast Pharma (ENLV) Israel $0.088B 0.00
Infinity Pharmaceuticals (INFI) United States $0.086B 0.00
SCYNEXIS (SCYX) United States $0.085B 0.00
Otonomy (OTIC) United States $0.081B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.079B 0.00
Genocea Biosciences (GNCA) United States $0.077B 0.00
Avenue Therapeutics (ATXI) United States $0.075B 0.00
India Globalization Capital (IGC) United States $0.066B 0.00
Capnia (SLNO) United States $0.064B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.063B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.058B 0.00
Forward Pharma (FWP) Denmark $0.056B 0.00
CTI BioPharma (CTIC) United States $0.055B 0.00
Melinta Therapeutics (MLNT) United States $0.048B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.048B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.048B 0.00
Bio-Path Holdings (BPTH) United States $0.045B 0.00
Lipocine (LPCN) United States $0.045B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.044B 0.00
KemPharm (KMPH) United States $0.044B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
BioLineRx (BLRX) Israel $0.040B 0.00
ContraFect (CFRX) United States $0.040B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.039B 0.00
Heat Biologics (HTBX) United States $0.038B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.035B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
HANCOCK JAFFE (HJLI) United States $0.032B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.028B 0.00
Shineco (TYHT) China $0.028B 4.69
IsoRay (ISR) United States $0.026B 0.00
Achieve Life Sciences (ACHV) United States $0.026B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.026B 3.36
PharmAthene (ALT) United States $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Jaguar Animal Health (JAGX) United States $0.023B 0.00
Onconova Therapeutics (ONTX) United States $0.023B 0.00
Biomerica (BMRA) United States $0.023B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.020B 0.00
NOVAN INC (NOVN) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
NanoViricides (NNVC) United States $0.019B 0.00
Pain Therapeutics (SAVA) United States $0.019B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.018B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.016B 0.00
Xenetic Biosciences (XBIO) United States $0.016B 0.00
ESSA Pharma (EPIX) Canada $0.015B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.014B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.013B 4.07
Regulus Therapeutics (RGLS) United States $0.012B 0.00
PRECISION THERAPEUTICS INC (AIPT) United States $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Can-Fite Biopharma (CANF) Israel $0.010B 0.00
Achaogen (AKAO) United States $0.010B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.009B 0.00
Trillium Therapeutics (TRIL) Canada $0.009B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
Midatech Pharma (MTP) United Kingdom $0.007B 0.00
VAXART, INC (VXRT) United States $0.006B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.006B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00